RxDoctor Payments DataLook up a doctor →

Tony Vanetesse, DO

Pain Medicine · Ephrata, PANPI 1295121390

Payments from drug & device makers

$16,678in general payments, 2019–2025

Across 448 payments — averaging $37.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$8K
  • Abbott$3K
  • MML US, Inc.$1K
  • Vertos Medical, Inc.$865
  • Relievant Medsystems, Inc.$667
  • Collegium Pharmaceutical, Inc.$486
  • plus $3K from 35 others
$335in research payments, 2019–2025

Across 3 payments — averaging $111.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Saluda Medical Americas, Inc.$335

What the payments were for

  • Speaking & faculty fees$1,5009%
  • Travel & lodging$2,39614%
  • Food & beverage$12,78177%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,678 in reported general payments places this provider in the 90th percentile of 294 pain medicine providers in Pennsylvania.

See all pain medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$172,118
Medicare patients
260
Services billed
8,138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl25$21,031
Nurtec OdtRimegepant Sulfate11$20,915
BelbucaBuprenorphine Hcl13$12,374
Xtampza ErOxycodone Myristate13$12,168
Oxycodone Hcl177$6,637
Morphine Sulfate ErMorphine Sulfate96$2,766
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen88$2,684
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen91$2,466
Oxymorphone Hcl ErOxymorphone Hcl11$2,041
Gabapentin38$1,354
Hydromorphone Hcl25$1,113
Morphine Sulfate27$751
Pregabalin20$667
Tizanidine Hcl37$666
Methadone Hcl24$531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$486$24,54226 claims
PfizerNurtec Odt$57$20,91511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 294 pain medicine providers in Pennsylvania.

Other pain medicine in Ephrata

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →